Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients

Joshua D. Palmer, Deepak Bhamidipati, Gaurav Shukla, Dinesh Sharma, Jon Glass, Lyndon Kim, James J. Evans, Kevin Judy, Christopher Farrell, David W. Andrews, Zi Wuan Wang, Stephen C. Peiper, Maria Werner-Wasik, Wenyin Shi

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objectives:Determine the prognostic significance of rapid early tumor progression before radiation and chemotherapy for glioblastoma patients.Methods:A retrospective review of glioblastoma patients was performed. Rapid early progression (REP) was defined as new enhancing tumor or >25% increase in enhancement before radiotherapy. The pre/postoperative magnetic resonance imaging was compared with the preradiation magnetic resonance imaging to determine REP. A blinded review of imaging was performed. Kaplan-Meier curves were generated to compare progression-free and overall survival (OS). Univariate analysis was performed using the log-rank test for categorical variables and Cox proportional hazards for continuous variables. Multivariable logistic regression was performed to assess factors related to early progression and Cox proportional hazards model was used for multivariate analysis of OS.Results:Eighty-seven patients met entry criteria. A total of 52% of patients developed REP. The OS in the REP group was 11.5 months (95% confidence interval [CI]: 7.4-17.6) and 20.1 months (95% CI: 17.8-26.1) without REP (P=0.013). On multivariate analysis including significant prognostic factors, presence of REP was found to increase the risk of death (hazard ratio: 2.104, 95% CI: 1.235-3.583, P=0.006). A total of 74% of patients recurred in the site of REP.Conclusions:REP was common and independently predicted for a worse OS. Integrating REP with MGMT promotor methylation improved prognostic assessment. The site of REP was a common site of tumor progression. Our findings are hypothesis generating and may indicate a particular subset of glioblastoma patients who are resistant to current standard of care therapy. Further study to determine other molecular features of this group are underway.

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - 1 May 2019
Externally publishedYes


  • MGMT
  • biomarker
  • early progression
  • glioblastoma
  • survival


Dive into the research topics of 'Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients'. Together they form a unique fingerprint.

Cite this